Allergy Shot Allergic Reaction: The Immunological Mechanism Explained

Allergy shots work by delivering controlled doses of the exact allergens you are sensitized to, training your immune system to tolerate them over time. But this training requires walking a narrow line: the dose must be high enough to promote regulatory T cell differentiation and IgG4 blocking antibody production, but below the threshold that triggers mast cell degranulation. During the build-up phase, when IgG4 levels are still low relative to IgE, this margin is narrow. At any injection where the dose slightly exceeds your current tolerance threshold, the allergen cross-links IgE on mast cells, triggering the same histamine release that causes your natural allergies. The reaction does not undo the progress — IgG4 accumulation continues — but it signals that the current dose needs adjustment. Most patients who have systemic reactions during build-up complete treatment successfully after dose reduction.

IgG4 blocking antibodies are a central mechanism by which allergy shot treatment reduces both allergic reactions and natural allergy symptoms. They are produced by B cells when regulatory T cells (induced by the tolerogenic SCIT protocol) signal a class-switch from IgE production to IgG4 production. IgG4 molecules bind to the same allergen epitopes as IgE but occupy Fc receptors without triggering mast cell activation. By competing with IgE for allergen binding, they effectively reduce the probability that any given allergen molecule will cross-link surface IgE on a mast cell. During maintenance SCIT, IgG4 blocking antibodies rise 10 to 100 fold above pre-treatment levels (Jutel et al., JACI 2005), progressively raising the dose required to trigger degranulation. This is why maintenance-phase injections — at the same doses that caused reactions during build-up — are typically well-tolerated.

No. Individual mast cell releasability varies approximately 100-fold between patients (Siraganian, JACI 2003), which explains why patients receiving identical doses from the same vial can have completely different reaction profiles. The threshold depends on the density of allergen-specific IgE on mast cell surfaces (determined by each patient's sensitization level), the accumulated IgG4 blocking antibody concentration, baseline mast cell sensitivity (which is higher in patients with mast cell disorders or elevated baseline tryptase), and cofactors including medications, concurrent illness, exercise, and pollen season. This inter-individual variability is the core reason allergy shots are personalized: each patient's starting dose and escalation rate are based on their specific IgE test results, and dose adjustments after reactions are individualized rather than protocol-fixed.

When the injection dose crosses the mast cell activation threshold, allergen molecules simultaneously bind multiple IgE molecules on the mast cell surface, aggregating FcepsilonRI receptors into clusters. This aggregation activates intracellular Lyn and Syk tyrosine kinases, triggering a cascade that leads to mast cell degranulation — the rapid release of pre-formed mediators stored in granules (histamine, tryptase, heparin) and the synthesis of new mediators (prostaglandins, leukotrienes, platelet-activating factor). Histamine acts on H1 receptors in skin capillaries (causing hives and flushing), bronchial smooth muscle (causing bronchoconstriction), and nasal mucosa (causing sneezing). Leukotrienes are more potent bronchoconstrictors than histamine and drive the sustained lower-respiratory component. Prostaglandins contribute to vasodilation and cardiovascular effects. The cascade progresses from local (injection site) to regional to systemic as mediator concentrations overwhelm local regulatory mechanisms.

The higher reaction rate during build-up reflects the immunological state at that stage of treatment. Early in build-up, allergen-specific IgE levels are at their highest relative to IgG4 blocking antibodies, which have not yet accumulated substantially. Each dose escalation in build-up pushes the dose higher while the protective IgG4 shield is still developing. Progressively, each injection adds to the IgG4 pool — but there is a lag between dose delivery and immune response. By the time maintenance is reached, the IgG4 blocking antibody pool has grown 10 to 100 fold above baseline, and the same doses that triggered reactions during escalation are now well below the mast cell activation threshold. The AAAAI/ACAAI surveillance data confirm this: 70 to 80% of all systemic reactions occur during build-up, with maintenance-phase SRs concentrated in risk windows such as new vial transitions and peak pollen season.

Antihistamines can reduce the frequency and severity of Grade 1 local and mild systemic reactions by blocking histamine H1 receptors downstream of mast cell degranulation — they reduce the symptoms caused by histamine release but do not prevent the degranulation event itself. For cluster and rush allergy shot protocols, antihistamine premedication is recommended and has demonstrated efficacy: Portnoy 1994 found a 27% systemic reaction rate with antihistamine premedication versus 73% without in rush immunotherapy. However, for standard conventional build-up schedules, routine antihistamine premedication is NOT recommended by AAAAI/ACAAI guidelines for two reasons: efficacy for conventional schedules is less clearly demonstrated, and antihistamines can mask early warning symptoms of developing anaphylaxis — delaying recognition of a worsening reaction. They do not prevent Grade 3-4 anaphylaxis, which is driven by leukotriene and prostaglandin mediators rather than histamine alone.

Several factors are documented to lower the mast cell activation threshold, making a previously tolerated dose more likely to cause a reaction. Exercise within 2 hours of injection increases blood flow to the injection site, accelerating systemic allergen absorption — effectively increasing the delivered dose rate. Peak pollen season adds environmental allergen to the injection burden, creating additive allergen load. Concurrent infection upregulates inflammatory signaling and FcepsilonRI receptor density on mast cells. Alcohol and vasodilating medications increase blood flow to the injection site. NSAIDs may increase mast cell releasability through prostaglandin pathway effects. Beta-blockers impair the compensatory epinephrine response if a reaction does occur. New vial transitions carry higher effective dose variability. AAAAI/ACAAI surveillance data (Epstein 2013) confirm that practices that systematically address modifiable risk factors — asthma screening, seasonal dose reduction, new vial protocols — have meaningfully fewer severe reactions.